CHMP recommends Velcade for treatment of Mantle Cell Lymphoma- Janssen Cilag.
O n 18 December 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Velcade. The marketing authorisation holder for this medicinal product is Janssen Cilag International N.V. The CHMP adopted a new indication as follows: "Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated Mantle Cell Lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.